Paroxetine Tablet (Extended-Release) Suppliers & Bulk Manufacturers
Available Forms: Tablet (Extended-Release)
Available Strengths: 12.5 mg, 25 mg, 37.5 mg
Reference Brands: US: Paxil®, Pexeva®, Brisdelle®; EU: Seroxat®, ParoMerck®, Paxetin®
Category: Antipsychotropic Drugs
Paroxetine extended-release is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin levels in the brain to improve mood and emotional stability. It is used to treat major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder, providing sustained symptom relief through its controlled-release formulation for once-daily dosing. Paroxetine Tablet (Extended-Release) is available in Tablet (Extended-Release) and strengths such as 12.5 mg, 25 mg, 37.5 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Paroxetine Tablet (Extended-Release) is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Paroxetine Tablet (Extended-Release) can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
Product Description: Paroxetine extended-release tablets are FDA-approved in the USA for treating major depressive disorder (MDD), panic disorder, social anxiety disorder, and generalized anxiety disorder. As a selective serotonin reuptake inhibitor (SSRI), they require a Boxed Warning for increased suicidality risk in young adults, along with compliance to GMP, labeling regulations, and post-marketing surveillance under FDA’s pharmacovigilance programs. In the EU, while immediate-release formulations are more common, extended-release versions must meet EMA or national agency approval standards, including Risk Management Plans (RMPs) and Periodic Safety Update Reports (PSURs). Explore dossier-ready supplies at Pharmatradz.com.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Related Products
Bupropion Hydrobromide
Strength:
75 mg, 100 mg, 150mg, 300 mg
Form: Tablets
Reference Brands: Wellbutrin (USA), Zyban (USA)
View Details
Amitriptyline Hydrochloride
Strength:
10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg
Form: Tablets
Reference Brands: Elavil (USA), Vanatrip (USA), Saroten (EU)
View Details
Olanzapine + Fluoxetine Hydrochloride
Strength:
6 mg + 25 mg , 3mg+25mg
Form: Capsules
Reference Brands: Symbyax (USA)
View Details
Nefazodone Hydrochloride
Strength:
50 mg, 100 mg, 150 mg, 200 mg,250 mg
Form: Tablets
Reference Brands: Serzone (USA)
View DetailsQuick Response Guaranteed | Verified Suppliers
